See more : Miroku Jyoho Service Co., Ltd. (9928.T) Income Statement Analysis – Financial Results
Complete financial analysis of Capstar Special Purpose Acquisition Corp. (CPSR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Capstar Special Purpose Acquisition Corp., a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- NSI N.V. (NSI.AS) Income Statement Analysis – Financial Results
- Norwest Energy NL (NWE.AX) Income Statement Analysis – Financial Results
- Banxa Holdings Inc. (BNXA.V) Income Statement Analysis – Financial Results
- Siam City Cement Public Company Limited (SCCC-R.BK) Income Statement Analysis – Financial Results
- Ion Electronic Materials Co., Ltd. (6959.TWO) Income Statement Analysis – Financial Results
Capstar Special Purpose Acquisition Corp. (CPSR)
About Capstar Special Purpose Acquisition Corp.
As of January 13, 2022, Capstar Special Purpose Acquisition Corp. was acquired by Gelesis, Inc., in a reverse merger transaction. Capstar Special Purpose Acquisition Corp. is a blank check company. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on businesses in the consumer, healthcare, and technology, media and telecommunications industries. The company was incorporated in 2020 and is based Austin, Texas.
Unable to fetch income statement for: CPSR
Gelesis, Maker Of Weight Loss Pill, Concludes SPAC Deal; Trading Kickstarts Today
PureTech Health plc (NASDAQ: PRTC) founded entity Gelesis Inc, maker of weight management aid, has completed its business combination with Capstar Special Purpose Acquisition Corp (NYSE: CPSR). The publicly-traded company will be Gelesis Holdings Inc and will begin trading on the New York Stock Exchange under the ticker...
Gelesis®, the Maker of Plenity® for Weight Management, Will Debut as a Publicly Traded Company Following the Closing of Its Business Combination with Capstar
BOSTON & AUSTIN, Texas--(BUSINESS WIRE)--Gelesis, the maker of Plenity®, an FDA-cleared weight management approach, announced today the completion of its business combination with Capstar Special Purpose Acquisition Corp. (NYSE: CPSR) (“Capstar”). The publicly traded company will be known as Gelesis...
Gelesis Adds Inogen Co-Founder and Former CFO Ali Bauerlein to Board of Directors and Audit Committee
BOSTON--(BUSINESS WIRE)--Gelesis, a biotherapeutics company focused on excess weight and metabolic disorders and the maker of Plenity®, announced the appointment of senior financial executive Ali Bauerlein to its Board of Directors. Ms. Bauerlein brings extensive experience in SEC reporting, Sarbanes-Oxley...
Have Your Cake and Eat It Too: Plenity® Creates Edible Dessert Billboard to Challenge Overly Restrictive Dieting Assumptions
BOSTON--(BUSINESS WIRE)--Gelesis, the maker of Plenity®, an FDA-cleared weight management approach, has created an edible billboard in New York City’s Astor Place to challenge the idea that people can’t eat the foods they love while losing weight. The billboard features...
Gelesis’ FDA-Cleared Weight Management Approach, Plenity®, Now Broadly Available and Leading Nutrition Authority Joy Bauer, MS, RDN, CDN, Joins as Chief Nutrition Officer
BOSTON--(BUSINESS WIRE)--Gelesis, a consumer-focused biotherapeutics company, is proud to announce Plenity®, an FDA cleared weight management approach, is now broadly available across the United States to adults who meet the prescription criteria. The company is also pleased to announce the...
Gelesis Receives $30 Million Plenity Order from Ro
BOSTON--(BUSINESS WIRE)--Gelesis announced today that leading U.S. direct-to-patient healthcare company Ro has placed a $30 million fully paid pre-order for the company’s first commercial product for weight management, Plenity®. Plenity was initially made available through a beta launch in 2020,...
Nature’s Scientific Reports Features Gelesis’ Novel and Foundational Biomimetic Platform for Treating Obesity and Conditions Related to Diet-Induced Gut Damage
BOSTON--(BUSINESS WIRE)--Gelesis, a consumer-focused biotherapeutics company and the maker of Plenity®, announced today a publication in Nature’s Scientific Reports describing the genesis of the underlying technology and engineering process for Gelesis’ non-systemic superabsorbent hydrogels. These new materials were designed to...
Two Senior Scientific Leaders at Gelesis Awarded Top Industry Honors
BOSTON--(BUSINESS WIRE)--Gelesis, a consumer-focused biotherapeutics company and the maker of Plenity®, announced that two senior leaders in the company, Elaine Chiquette, Pharm.D., and Elizabeth Pash, MS, RD, LDN, were recognized with top industry honors for their work. Chiquette, Gelesis’ Chief...
FDA-Approved Weight Loss Drug Plenity's Parent Announces SPAC Deal: What Investors Should Know
A SPAC deal announced Monday could help accelerate the manufacturing of a promising weight loss drug targeting over 150 million people. The SPAC Deal: Gelesis announced a SPAC merger with Capstar Special Purpose Acquisition Corp (NYSE:CPSR).
Gelesis, a Consumer-Focused Biotherapeutics Company and the Maker of Plenity®, to Become a Publicly Traded Company via Merger with Capstar Special Purpose Acquisition Corp.
BOSTON & AUSTIN, Texas--(BUSINESS WIRE)--Gelesis, Inc. (“Gelesis” or the “Company”), a biotherapeutics company advancing biomimetic superabsorbent hydrogels to treat excess weight and metabolic disorders, and Capstar Special Purpose Acquisition Corp. (NYSE: CPSR) (“Capstar”), a special purpose acquisition company sponsored by...
Source: https://incomestatements.info
Category: Stock Reports